CRCL is down -5.43% to roughly $90.36 in regular trading, deepening an earlier premarket decline of about -2.5%. The drop is rates-driven risk-off: the 10-year Treasury yield hit 4.79%, a fresh 52-week high, squeezing valuations of high-beta crypto equities.

ARM fell -5.15% to $229.44 in the regular session, down from its prior close of $241.91. The drop is macro-driven, not company-specific: a global bond selloff pushed the 10-year Treasury yield to a multi-year high near 4.8%, pressuring high-multiple AI/semiconductor valuations.

RZLV fell -12.11% in regular trading, dropping from a $2.89 prior close to roughly $2.54 after the open. The sell-off followed Rezolve AI's quarterly earnings, which missed expectations and triggered sharp selling.

ALMS plunged roughly -53% (about $10.22 vs. prior close $21.81) in premarket trading before reopening lower at the open. Primary catalyst: the Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus missed its primary and secondary endpoints in the overall population.

PURR is the Nasdaq-listed ticker for Hyperliquid Strategies, Inc., a digital asset treasury company focused on the Hyperliquid Layer-1 blockchain ecosystem and its native token, HYPE. The company was founded in July 2025 and is headquartered in New York City.

AAOI is the ticker for Applied Optoelectronics, Inc. , a vertically integrated designer and manufacturer of fiber-optic networking and optical communications products. The company serves four primary end markets: internet data centers, cable television (CATV), telecommunications, and fiber-to-the-home (FTTH).

Palantir Technologies Inc. is a U.S.-based software company specializing in data integration, analytics, and artificial intelligence platforms for government and commercial clients. The company was founded in 2003 and has become known for its work with defense, intelligence, and large enterprise customers.

NI closed up +0.86% at $40.92 in Monday's regular session, versus a prior close of $40.57. The move was a modest technical bounce following a steep pullback—shares remain down roughly -8% over the past month and well below their ~$49 52-week high.

Opendoor Technologies shares fell roughly 15% over the trailing 30 days, from about $3.77 to near $3.20. The decline followed second-quarter 2026 results reported on August 4, 2026, which showed revenue missing estimates and a widening net loss despite improved operational metrics.

NVMI closed down -0.17% (-$0.61) at $348.45 in Monday's regular session, its most recent trading day. The move was a low-volume drift (about 163K shares vs. a ~541K average) with no major company-specific catalyst.

FuelCell Energy (FCEL) shares fell roughly 20.3% over the last 30 days, declining from a closing price of $21.61 on July 31, 2026, to $17.23 by August 31, 2026. The pullback followed a sharp, news-driven rally in late June that carried the stock to a closing peak near $36, leaving the shares exposed to profit-taking and renewed volatility.

LII fell -2.73% to $382.64 during the Aug 31 regular session, hitting a fresh 52-week low on above-average volume. The drop extends a post-earnings selloff tied to its late-July Q2 report, which missed revenue and cut FY2026 EPS guidance to $23.00–$24.00.

AppLovin shares fell roughly 21% over the last 30 days, from about $395.90 to $312.06, extending a steeper multi-month pullback. The decline was triggered by second-quarter 2026 results that missed revenue and adjusted EBITDA expectations and a Q3 outlook that landed slightly below consensus.

Western Digital shares fell roughly 17% over the last 30 days, from a closing price of $544.84 on July 31 to $450.55 on August 31. The decline followed fiscal Q4 FY2026 results that beat analyst estimates yet still triggered heavy selling as guidance failed to satisfy elevated AI-storage expectations.

AMLX shares climbed roughly 66% over the last 30 days, rising from $20.31 to $33.75, driven by positive late-stage clinical data for its lead drug candidate, avexitide. On August 18, 2026, Amylyx reported that avexitide met its primary endpoint in the Phase 3 LUCIDITY trial, cutting severe hypoglycemic events by 55% versus placebo in post-bariatric hypoglycemia (PBH).

Chime Financial (CHYM) climbed roughly 44% over the trailing 30 days, rising from about $22.99 at the end of July to $33.11 at the end of August 2026. The advance was driven primarily by a strong Q2 2026 earnings report, which delivered a second consecutive quarter of GAAP profitability and a raised full-year outlook.

PURR shares climbed roughly 97% over the past 30 days, from a close of about $6.21 on July 31 to $12.25 on Aug. 31. The rally was driven chiefly by a surge in HYPE, the Hyperliquid token that anchors the company's treasury, combined with a strong fiscal-year report.

Where a stock is expected to go next? That’s one of the ideas behind Tickeron Ask AI — helping retail traders quickly understand market expectations without digging through dozens of analyst reports and news articles.

Build your own community around your trading interests and market ideas. Create original financial blogs in one click using insights from Ask AI. Keep your audience engaged with fresh content about stocks, earnings, news, forecasts and market moves. Share Tickeron AI tools and trading ideas that you find useful.

Ask AI combines market news, corporate events, analyst research, and Tickeron's proprietary Financial Learning Models (FLMs) to help investors quickly understand what is driving a stock—without spending hours researching multiple sources.